HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...

Boston Scientific has signed a deal to acquire the maker of a chemotherapy infusion pump aimed at treating certain inoperable ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

Six years after first allying with Aelix Therapeutics to test the Spanish biotech’s HTI vaccine for HIV, Gilead Sciences has ...

Abbott has taken a step forward in the development of a new addition to its structural heart portfolio, completing the first ...

A phase 3 trial of Biohaven’s taldefgrobep alfa in spinal muscular atrophy (SMA) has missed its primary endpoint. The biotech ...

To recruit volunteers more quickly for clinical trials, a team of National Institutes of Health (NIH) researchers has turned ...

Adcendo is adding $135 million to its arsenal, money that will go toward launching several antibody-drug conjugate (ADC) ...

Advantage Therapeutics is spinning off some of its age-related disease R&D into a new company called Klothea Bio. | Klothea ...

The annual Fierce 50 Gala is set to shine a spotlight on the life sciences industry's most transformative leaders, ...

A patient has died after receiving the high dose of Neurogene’s Rett syndro | A patient has died after receiving the high ...

AstraZeneca has ended work on an opioid use disorder (OUD) drug after the orexin 1 receptor antagonist demonstrated a ...